Kite Pharma A Top Pick Ahead Of Axi-Cel Launch

By: via Benzinga
Kite Pharma Inc (NASDAQ: KITE) is preparing to launch Axi-Cel, a chimeric antigen receptor T-cell therapy for non-Hodgkin’s ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.